<DOC>
	<DOCNO>NCT00768404</DOCNO>
	<brief_summary>VI-0521 , fix dose combination immediate-release ( IR ) phentermine controlled-release ( CR ) topiramate , Phase III clinical development potential therapy obesity . In human , phentermine topiramate primarily clear renal excretion . The contribution hepatic metabolism elimination phentermine topiramate significant . Obese patient , propose indicated population future treatment VI-0521 , likely renal impairment . Therefore , study important understanding effect renal impairment pharmacokinetics topiramate phentermine subject renal impairment compare subject normal renal function .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics VI-0521 Subjects With Renal Impairment</brief_title>
	<detailed_description>This open-label , parallel-group , single dose , non-randomized study conduct multiple site United States 40 male female subject , 19-75 year age ( inclusive ) , vary degree renal function may enrol dosed obtain least 32 evaluable subject ( 4 group , 8 subject per group ) . Subjects report study site evening treatment remain site 48-hour PK sample drawn ( approximately 3 day ) . All subject fast overnight minimum 8 hour drug treatment morning . A single oral dose combination product VI-0521 ( 15 mg phentermine 92 mg topiramate ) administer 240 mL water hour 0 . Standard meal provide uniformly subject approximately 4 9 hour dose , even snack provide approximately 12 - 13 hour dose . Blood sample determination phentermine topiramate concentration plasma collect 0 ( pre-dose ) , 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 16 , 24 , 36 48 hour post dose . Subjects release study site follow 48-hour sample return site PK sample 72 , 96 , 120 , 144 , 168 192 hour post dose . The severe renal impairment group give option stay site duration study .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Group 1 consist 810 male female normal renal function , 1975 year age , inclusive . Groups 24 consist 810 male female per group vary degree stable renal impairment A history presence significant cardiovascular , neurological , hematological , psychiatric , hepatic , gastrointestinal , pulmonary , endocrine , immunologic renal disease condition know interfere absorption , distribution , metabolism , excretion drug place subject increase risk determine investigator ; history glaucoma , increase intraocular pressure , medication treat increase intraocular pressure ; presence cholelithiasis cholecystitis within last 6 month surgically treat cholecystectomy ; history cardiovascular cerebrovascular event ; subject require dialysis ; active malignancy except basal cell carcinoma ; systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 100 mm Hg screening checkin ( 2 rechecks allow ) ; Hemoglobin &lt; 12.0 g/dL Group 1 ( patient normal renal function ) ; Hemoglobin &lt; . 9.0 g/dL Groups 2 , 3 4 ( patient mild severe renal function ) positive drug/alcohol test screen check ; blood donation significant blood loss within 56 day dose ; plasma donation within 7 day dose . In female subject , positive pregnancy test screen checkin exclusionary</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>